Global digital health company, Huma Therapeutics has announced the acquisition of Alcedis, a data driven clinical research and technology company.
Through the acquisition, Huma will form an advanced clinical trials division offering digital solutions across the entire development pipeline, from early stage through to Phase IV hybrid and fully decentralized trials.
Integrating Alcedis' clinical and operational know-how with Huma's digital expertise will make Huma the optimal healthtech provider, able to support the seamless integration of digital technology into clinical trials.
Between them, Huma and Alcedis have managed nearly a thousand studies across a wide range of therapeutic areas, including rare diseases, oncology, immunology, cardiovascular, respiratory, neurodegenerative, musculoskeletal, dermatology and metabolic diseases, in over 60 countries involving more than 650,000 participants.
Dan Vahdat, CEO & Founder of Huma, said: "Huma has been a leader in digital-first care and research, partnering with health systems and pharma companies and now with this acquisition we're set to redefine the clinical trials sector."
Hanno Härtlein, Managing Director Alcedis, said: "Together, we will offer substantially greater benefit to pharmaceutical, MedTech, clinical research organizations, and academic partners for their research projects."
Join the HealthXL Meeting on ‘How Can Virtual Care Solutions Help Health Systems Bounce Back After Covid?’ on 26th January. Click here to Request to Join.
Click here to read the original news story.